This full-day workshop will cover a broad range of critical concepts underlying assay development and implementation for high-throughput screening (HTS) and lead discovery projects. Many of the methodologies successfully implemented in such projects have established a good deal of “tribal knowledge” within the pharmaceutical industry and are not readily found in a classroom or literature. This tribal knowledge, developed over decades, has been transferred into detailed chapters within the Assay Guidance Manual to facilitate reproducible and robust assays that can identify the most promising compounds for the development of molecular probes or clinical candidates.
The target audience is individuals involved in bioassay development for drug discovery and development. The AGM and this workshop will be a valuable resource for academic, industrial and government laboratory scientists who are planning or beginning to develop test methods for high- or low-throughput screening who are amenable to automation using appropriate statistical and operational concepts. The workshop will also be useful for early career researchers and experienced investigators who wish to learn about the latest assay concepts for HTS and lead optimization
Participants will gain a broad, practical perspective on assay development so that they can (1) improve research projects involving drug discovery and know where to find further information (2) identify reagents, methods and instrumentation that are well suited to robust assays (3) be able to develop robust assays and counter assays for new targets. Additionally, participants will have the opportunity to seek practical advice about individual research challenges.
8:00 a.m. – 8:20 a.m. | Robust or Go Bust: An Introduction to the Assay Guidance Manual G. Sitta Sittampalam, Ph.D., NCATS/NIH |
8:20 a.m. – 9:05 a.m. | Target Qualification Strategies Yueming Wang, Ph.D., Pfizer |
9:10 a.m. – 9:55 a.m. | Strategies for Assay Selection and for the Development of Robust Biochemical Assays Nathan P. Coussens, Ph.D., Frederick National Laboratory for Cancer Research |
10:00 a.m. – 10:30 a.m. | Beverage Break |
10:30 a.m. – 11:15 a.m. | Treating Cells as Reagents to Design Reproducible Screening Assays Terry Riss, Ph.D., Promega Corporation |
11:15 a.m. – 12:00 p.m. | HCS Assay Development Joe Trask, PerkinElmer |
12:00 p.m. – 1:00 p.m. | Lunch |
1:00 p.m. – 1:45 p.m. | Bioassay Interference by Aggregation and Chemical Reactivity Jayme L. Dahlin, M.D., Ph.D., Brigham and Women’s Hospital |
1:45 p.m. – 2:30 p.m. | Kinetics of Target Binding: Kinetic Artifacts in Potency Assays and Methods for Measuring Binding Kinetics Sam Hoare, Ph.D., Pharmechanics LLC |
2:30 p.m. – 3:00 p.m. | Beverage Break |
3:00 p.m. – 3:40 p.m. | Basic Assay Statistics, Data Analysis and Rules of Thumb Thomas D.Y. Chung, Ph.D., Sanford Burnham Prebys Medical Discovery Institute |
3:40 p.m. – 4:20 p.m. | A Simple Metric for Comparing Compound Potency Results and Characterizing Assay Reproducibility Viswanath Devanarayan, Ph.D., GlaxoSmithKline |
4:20 p.m. – 5:00 p.m. | Lead Selection and Optimization by Medicinal Chemistry Samarjit Patnaik, Ph.D., NCATS, NIH |
5:00 p.m. | Adjourn |
Diamond Sponsor
Diamond Sponsor
Diamond Sponsor
Diamond Sponsor
Diamond Sponsor
Diamond Sponsor
Platinum Sponsor
Platinum Sponsor
Platinum Sponsors
Platinum Sponsor
Platinum Sponsor
Platinum Sponsor
Gold Sponsor
Gold Sponsor
Gold Sponsor
Gold Sponsor
Silver Sponsor
Silver Sponsor
Silver Sponsor
Silver Sponsor
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner
Media Partner